Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2025-12-25 @ 10:56 PM
Study NCT ID:
NCT00601367
Status:
COMPLETED
Last Update Posted:
2014-06-20
First Post:
2008-01-15
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Sponsor:
Sprout Pharmaceuticals, Inc
Organization:
Study Overview
Official Title:
A Twenty-Eight Week, Open-Label, Safety Study of Flibanserin 50 Mgs to 100 Mgs Daily in Premenopausal European Women With HSDD
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: